Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.42 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2917080 | 1.00 | HSD17B10 (0.49) | HSD17B10LMNANPSR1SMN1; SMN2NPC1 | |
| SCHEMBL2913447 | 1.00 | HSD17B10 (0.49) | HSD17B10LMNANPSR1SMN1; SMN2NPC1 | |
| SCHEMBL2917078 | 1.00 | HSD17B10 (0.49) | HSD17B10LMNANPSR1SMN1; SMN2NPC1 | |
| SCHEMBL2913444 | 1.00 | HSD17B10 (0.49) | HSD17B10LMNANPSR1SMN1; SMN2NPC1 | |
| SCHEMBL15731577 | 0.90 | CHRM2 (0.45) | HSD17B10LMNANPSR1SMN1; SMN2CHRM2 | |
| SCHEMBL31153617 | 0.90 | CHRM2 (0.45) | HSD17B10LMNANPSR1SMN1; SMN2CHRM2 | |
| SCHEMBL29222095 | 0.90 | CHRM2 (0.45) | HSD17B10LMNANPSR1SMN1; SMN2CHRM2 | |
| SCHEMBL4468362 | 0.90 | CHRM2 (0.45) | HSD17B10LMNANPSR1SMN1; SMN2CHRM2 | |
| SCHEMBL20514898 | 0.90 | CHRM2 (0.45) | HSD17B10LMNANPSR1SMN1; SMN2CHRM2 | |
| SCHEMBL2198040 | 0.90 | CHRM2 (0.45) | HSD17B10LMNANPSR1SMN1; SMN2CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250026736-A1 | 3-(5-oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione Derivatives and Uses thereof | NOVARTIS AG (CH) | 2025-01-23 | — | — | US | disclosed |
| US-12103919-B2 | 3-(5-oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof | NOVARTIS AG (CH) | 2024-10-01 | — | — | US | disclosed |
| CN-117062811-A | 3- (1-oxo-isoindolin-2-yl) piperidine-2, 6-dione derivatives and medical use thereof | 诺华股份有限公司 | 2023-11-14 | — | — | CN | disclosed |
| US-20230019617-A1 | 3-(5-oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione Derivatives and Uses thereof | NOVARTIS AG (CH) | 2023-01-19 | — | — | US | disclosed |
| EP-2010506-B1 | DIAZEPAN DERIVATIVES MODULATORS OF CHEMOKINE RECEPTORS | HOFFMANN LA ROCHE (CH) | 2010-08-04 | — | — | EP | disclosed |
| US-7632829-B2 | Diazepan derivatives | HOFFMANN-LA ROCHE INC. (US) | 2009-12-15 | — | — | US | disclosed |
| EP-2010506-A1 | DIAZEPAN DERIVATIVES MODULATORS OF CHEMOKINE RECEPTORS | F. Hoffmann-Roche AG (CH) | 2009-01-07 | — | — | EP | disclosed |
| WO-2007122103-A1 | DIAZEPAN DERIVATIVES MODULATORS OF CHEMOKINE RECEPTORS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-11-01 | — | — | WO | disclosed |
| US-20070249589-A1 | Novel diazepan derivatives | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2007-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250026736-A1 | 3-(5-oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione Derivatives and Uses thereof | HBZ, HBG1, HBG2 | HSD17B10 2016/4885LMNA 1835/4885NPSR1 4687/4885 |
| US-20230019617-A1 | 3-(5-oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione Derivatives and Uses thereof | HBZ, HBG1, HBG2 | HSD17B10 2016/4885LMNA 1835/4885NPSR1 4687/4885 |
| US-12103919-B2 | 3-(5-oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof | HBZ, HBG1, HBG2 | HSD17B10 2016/4885LMNA 1835/4885NPSR1 4687/4885 |
| US-20070249589-A1 | Novel diazepan derivatives | CCR3, CCR1, CCR10 | HSD17B10 3681/4885LMNA 3307/4885NPSR1 143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.